The meta-analysis that pooled data from five trials showed increased risk of admission for HF in patients treated with DPP-4 inhibitors versus control, but with borderline significance (HR 1.13; 95%CI 1.00–1.26) [ 56 ].
1
—
—
The meta-analysis that pooled data from five trials showed increased risk of admission for HF in patients treated with DPP-4 inhibitors versus control, but with borderline significance (HR 1.13; 95%CI 1.00–1.26) [ 56 ].